Showing results (271-280 of 366) with videos related to
Sort By:
Pageof 37
Oncogene|February 26, 2020
Correction: Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinasesChi Zhang, Simon R Stockwell, May Elbanna, et al.Oncogene|July 13, 2019
Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinasesChi Zhang, Simon R Stockwell, May Elbanna, et al.Journal of Molecular Biology|February 6, 2007
A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimeraThomas G Davies, Marcel L Verdonk, Brent Graham, et al.Plos One|July 14, 2017
In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cellsNada M S Al-Saffar, Alice Agliano, Lynley V Marshall, et al.Nature Communications|February 17, 2026
R-loop editing by DNA cytosine deaminase APOBEC3B modulates the activity of oestrogen receptor enhancersChi Zhang, Yu-Jing Lu, Bingjie Chen, et al.Bioorganic & Medicinal Chemistry Letters|February 17, 2006
4-Amino derivatives of the Hsp90 inhibitor CCT018159Xavier Barril, Mandy C Beswick, Adam Collier, et al.The Journal of Biological Chemistry|August 25, 2004
Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosisGareth J Griffiths, Mei Yee Koh, Valerie G Brunton, et al.Plos One|August 2, 2014
Lactate and choline metabolites detected in vitro by nuclear magnetic resonance spectroscopy are potential metabolic biomarkers for PI3K inhibition in pediatric glioblastomaNada M S Al-Saffar, Lynley V Marshall, L Elizabeth Jackson, et al.ACS Chemical Biology|September 22, 2011
Targeting the Hsp90 molecular chaperone with novel macrolactams. Synthesis, structural, binding, and cellular studiesJames E H Day, Swee Y Sharp, Martin G Rowlands, et al.Journal of Medicinal Chemistry|June 25, 2005
Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based designBrian W Dymock, Xavier Barril, Paul A Brough, et al.Pageof 37